Effects of Acute Long-acting Bronchodilation on Oxygenation and Peripheral Ventilation in COPD - Trial NCT05927155
Access comprehensive clinical trial information for NCT05927155 through Pure Global AI's free database. This Phase 3 trial is sponsored by Erasme University Hospital and is currently Completed. The study focuses on Pulmonary Disease, Chronic Obstructive. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Erasme University Hospital
Timeline & Enrollment
Phase 3
Jun 15, 2021
Mar 30, 2022
Primary Outcome
Tissue oxygenation (TcO2) change from baseline,Tissue oxygenation (TcO2) change from baseline
Summary
The goal of this clinical trial was to compare the action of long-acting ร2-agonists
 (LABA-olodaterol) and muscarinic antagonists (LAMA-tiotropium) on tissue oxygenation in COPD
 considering their impact on proximal and peripheral ventilation and, eventually, on lung
 capillary volume. The hypothesis was that LABA would have a more peripheral effect than LAMA
 (due to the opposite gradient of their receptors) and better peripheral ventilation would
 result in a greater oxygenation.
 
 Before and after LABA (visit 1) and LAMA (visit 2) inhalation, COPD participants were asked
 to perform single-breath washout and forced oscillation tests, double diffusion technique and
 spirometry, while transcutaneous oxygenation was continuously recorded.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05927155
Non-Device Trial